A clinical trial to test a universal flu vaccine is under way, based on messenger RNA technology that was behind Moderna’s and Pfizer’s COVID-19 vaccines, the National Institutes of Health announced.
The Phase 1 trial will include 50 healthy people between 18 and 49. It will explore the safety of the experimental vaccine and its inducement of an immune response, the NIH said. It also will be compared against shots currently available.
The NIH says seasonal influenza, or flu, kills thousands of people in the U.S. each year. The CDC says between 12,000 and 52,000 people died of flu every year in this country between 2010 and 2020.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Hyperbaric Oxygen May Improve Heart Function in Long COVIDHyperbaric oxygen therapy increased markers of heart function in patients with post-COVID syndrome or long COVID, in a small, randomized trial.
Read more »
COVID Vaccines May Fade Quicker if You're Obese, Evidence ShowsCOVID-19 vaccines are very effective, but for some groups they don't generate as strong an immune response.
Read more »
Needle-free Covid vaccination trials taking place in CambridgeTrials are taking place in Cambridge, where the technology was developed.
Read more »
How hybrid work has changed the real estate market for both offices and apartmentsHow cool is this: TREO Apartments in Cleveland, constructed after the pandemic, feature a special work-at-home space in all 170 units.
Read more »
Covid-19 is no longer a public health emergency, but others remain | CNNCovid-19 and mpox hit milestones recently as public health emergency declarations were ended by both the United States government and the World Health Organization. But opioids remain an emergency in the US and poliovirus globally.
Read more »
Cook County Health ending mask requirements from COVID-19 public health emergencyStarting Monday, masks will no longer be required for most patients, staff, and visitors.
Read more »